|
| Exchange Disseminated Time | Claris Lifesciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on January 07, 2014, inter alia, has transacted the following businesses:
1. The Board has approved the buyback of upto 92,50,000 (Ninety Two Lacs Fifty Thousand) Equity Shares of the Company (the “Equity Shares”) of the face value of Rs. 10 each (representing 14.49% of the total number of the Equity Share Capital of the Company) at a price of Rs. 250 per Equity Share aggregating to Rs. 2,31,25,00,000 (Rupees Two Hundred Thirty One Crores Twenty Five Lacs only) through the "Tender Offer" route as prescribed under the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 1998, as amended (the "Buyback Regulations") on a proportionate basis from the shareholders as on the record date, subject to the approval of shareholders by way of a special resolution through postal ballot and regulatory compliances required under applicable laws.
The Board noted the intention of the Promoter and Promoter Group of the Company to participate in the proposed buyback.
The Board has formed a Committee (the "Buyback Committee") and has delegated its powers to the Buyback Committee to do all such acts, deeds, matters and things as it may, in its absolute discretion, deem necessary, expedient, usual or proper in connection with the buyback.
2. The Board has declared Interim Dividend of Rs. 9 (Nine) per Equity Share of Rs. 10 each of the Company.
Further the Board has decided that, the Interim Dividend will be paid/dispatched to the Equity Shareholders of the Company on February 04, 2014. |
|
|